REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com

REGENXBIO (NASDAQ:RGNX) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also weighed in on RGNX. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and decreased their price target for the company from $38.00 to $14.00 in a research report on Tuesday. Raymond James started coverage on REGENXBIO in a report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.45.

REGENXBIO Trading Down 0.3 %

Shares of NASDAQ:RGNX opened at $7.30 on Friday. The stock has a market cap of $361.68 million, a PE ratio of -1.45 and a beta of 1.29. The stock’s fifty day simple moving average is $7.88 and its two-hundred day simple moving average is $9.84. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80.

Institutional Investors Weigh In On REGENXBIO

Several institutional investors have recently added to or reduced their stakes in RGNX. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. Price T Rowe Associates Inc. MD grew its position in REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after buying an additional 1,982 shares in the last quarter. Teacher Retirement System of Texas increased its stake in REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,088 shares during the last quarter. nVerses Capital LLC raised its holdings in shares of REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,200 shares in the last quarter. Finally, DnB Asset Management AS boosted its position in shares of REGENXBIO by 20.1% during the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 2,434 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.